Abstract 4354
Background
Patients’ perception of clinical trials in Poland is mostly influenced by mass media. The image of CTs is often biased which may have an impact on recruitment.
Methods
Based on an anonymous 25-item Paper and Pencil Interview (PAPI) survey among 191 hospitalized oncological patients we analyzed knowledge, perception, willingness to participate and future expectations of CTs. Nominal scale: Yes/No/Don’t know, Likert scale of 0-5 points and multiple choice questions were applied.
Results
The majority of respondents were: (1) women: 70,2%, (2) people with secondary education: 57,6%, (3) at the age of 60-69: 41,9%, (4) living in cities over 100k inhabitants: 46,1%. Main findings 49,2% of respondents agreed to be enrolled in CTs; 15,3% refused and 35,4% were not certain. Among the driving factors for “YES” were: chance for a better/constant care - 76,3% and access to additional monitoring - 73,1%. 57,0% of respondents declared altruistic reason. The main reasons for not participating were: concern about toxicity - 62,1%, lack of efficacy - 55,2% and being a “guinea pig” - 41,4%. Among respondents uncertain about participation in CT, the factors of the highest impact on potential enrollment were: terminal phase of the disease/no other option: 68,7%/ 56,7%. The incentive of the family member or friend does not have a significant impact - only 19,4% respondents would follow it. Other findings 55,8%/ 54,7% of respondents do not know about the existence of any legal acts/state institutions that oversee CTs. 60,8% of respondents do not know whether there are independent bioethical committees that approve each CT prior to launch. 64,9% of respondents think that research funded by pharma companies is NOT as reliable as that of independent sources eg. medical universities. 76,2% of respondents think that the current amount of information on CTs is insufficient and 87,2% would like to know more.
Conclusions
The level of knowledge about CTs among patients is insufficient but the willingness to participate is high which is mainly driven by a possibility of a better and constant care. The trust in the pharmaceutical industry should be increased.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Kotowski: Full / Part-time employment: Roche Polska sp z o.o. All other authors have declared no conflicts of interest.
Resources from the same session
5655 - Bioactivation of napabucasin triggers reactive oxygen species–mediated cancer cell death
Presenter: Fieke Froeling
Session: Poster Display session 3
Resources:
Abstract
4097 - Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option
Presenter: Stephen V Liu
Session: Poster Display session 3
Resources:
Abstract
1129 - Aspirin and Ticagrelor for the prevention of tumour cell induced platelet aggregation
Presenter: Meera Chauhan
Session: Poster Display session 3
Resources:
Abstract
4514 - Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Presenter: Michele Maio
Session: Poster Display session 3
Resources:
Abstract
5169 - In vitro functional interrogation of viable Circulating Tumor Associated Cells (C-TACs) for evaluating Platin resistance.
Presenter: Stefan Schuster
Session: Poster Display session 3
Resources:
Abstract
5827 - Targeting ARG2 as a novel therapeutic approach for cancer
Presenter: Marcin Grzybowski
Session: Poster Display session 3
Resources:
Abstract
3129 - MPS1 and PLK1 as new therapy targets in TP53 mutated solid tumors
Presenter: Balazs Gyorffy
Session: Poster Display session 3
Resources:
Abstract
2129 - The Tumor Static Exposure (TSE) concept & utility: application to combination treatment of radiation and radiosensitizing agent in tumor xenograft experiments
Presenter: Samer El Bawab
Session: Poster Display session 3
Resources:
Abstract
1814 - General Methodology to Optimize Tumor Treating Fields Delivery Utilizing Numerical Simulations
Presenter: Noa Urman
Session: Poster Display session 3
Resources:
Abstract
3010 - The Australian Exceptional Responders Program: a National collaboration
Presenter: Megan Barnet
Session: Poster Display session 3
Resources:
Abstract